Naivek Announces Joint Research with UK IntractPharma... Oral 'Inflammatory Bowel Disease Treatment'
[Asia Economy Reporter Hyungsoo Park] Naivek, a peptide fusion bio-specialized company, announced on the 23rd that it has been invited to an international conference attended by global pharmaceutical companies and world-renowned scholars to present research results on the oral inflammatory bowel disease treatment ‘NIPEP-IBD,’ which is being jointly researched with the UK bio company ‘Intract Pharma.’
The international conference is the ‘IBD INNOVATE Conference,’ hosted annually in the United States by the Crohn’s & Colitis Foundation. It is attended by leading global scholars and pharmaceutical companies researching inflammatory bowel disease treatments and will be held offline for three days from January 20 to 22 next year in Las Vegas, USA.
Naivek will attend this conference to hold meetings with global pharmaceutical companies and present research results. The company will disclose the stability of the formulation and efficacy evaluation results in animal models, focusing on the oral NIPEP-IBD, which is being jointly developed with the UK’s Intract Pharma.
NIPEP-IBD is preparing for clinical phase 1 by signing a contract with a European CRO. At the conference, the company plans to present major research results conducted so far at the preclinical stage, and global pharmaceutical companies are showing great interest, according to the company.
A Naivek official said, “NIPEP-IBD not only has the function of suppressing inflammation in the intestines but also has the effect of regenerating the intestinal mucosa damaged by inflammation,” adding, “It is receiving significant attention at the international conference because it is expected to have synergy through combination therapy with existing immune treatments.”
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051414165763158_1778735817.jpg)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- [Breaking] Park Sukeun, Central Labor Relations Commission Chair: "Some Gaps Narrowed Between Samsung Electronics Labor and Management"
- Is This the Peak? As Others Hesitate..."The Answer Is Clear for Surviving the KOSPI 10,000 Era"
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
He continued, “Inflammatory bowel disease is a field that receives great attention in the bio-pharmaceutical market because there are no successful treatments developed yet,” emphasizing, “Naivek plans to rapidly advance new drug development.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
